Arch Point Investors Neurocrine Biosciences Inc Transaction History

Arch Point Investors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$89.43 - $102.27 $3.67 Million - $4.2 Million	-41,021 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $408,680 - $574,387	4,250 Added 11.56%	41,021 $3.95 Million
Q2 2020 Jul 31, 2020	BUY	$85.09 - $130.36 $42,545 - $65,180	500 Added 1.38%	36,771 $4.49 Million
Q1 2020 May 13, 2020	SELL	$75.11 - $113.76 $37,555 - $56,880	-500 Reduced 1.36%	36,271 $3.14 Million
Q4 2019 Feb 12, 2020	BUY	$86.8 - $118.57 $43,400 - $59,285	500 Added 1.38%	36,771 $3.95 Million
Q3 2019 Nov 13, 2019	SELL	$83.82 - $101.5 $188,594 - $228,375	-2,250 Reduced 5.84%	36,271 $3.27 Million
Q2 2019 Jul 26, 2019	SELL	$72.24 - $91.27 $45,150 - $57,043	-625 Reduced 1.6%	38,521 $3.25 Million
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $43,318 - $57,206	625 Added 1.62%	39,146 $3.45 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $1.54 Million - $2.8 Million	22,553 Added 141.24%	38,521 $2.75 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $1.2 Million - $1.69 Million	15,968 New	15,968 $1.57 Million

655

96.7M

316K

300K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Arch Point Investors, based on Form 13F filings with the SEC.

Stay updated on Arch Point Investors with notifications on news.